BDBM295687 US10851091, U.S. Pat. No. 8,263,633 No. 356::US8242104, Compound 356
SMILES: CC(C)(O)Cn1cc(cn1)-c1ccc2-c3nc(sc3CCOc2c1)N1C(=O)OCC1(C)C
InChI Key: InChIKey=DNWLWWRXENCXEL-UHFFFAOYSA-N
Data: 4 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Homo sapiens (Human)) | BDBM295687 (US10851091, U.S. Pat. No. 8,263,633 No. 356 | US82...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.920 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform... | US Patent US10112932 (2018) BindingDB Entry DOI: 10.7270/Q2JQ132B | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (Homo sapiens (Human)) | BDBM295687 (US10851091, U.S. Pat. No. 8,263,633 No. 356 | US82...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.920 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ... | US Patent US10851091 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (Homo sapiens (Human)) | BDBM295687 (US10851091, U.S. Pat. No. 8,263,633 No. 356 | US82...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.967 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ... | US Patent US10851091 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
PI3-kinase class I (Homo sapiens (Human)) | BDBM295687 (US10851091, U.S. Pat. No. 8,263,633 No. 356 | US82...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.967 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform... | US Patent US10112932 (2018) BindingDB Entry DOI: 10.7270/Q2JQ132B | |||||||||||
More data for this Ligand-Target Pair |